FARGO, N.D., March 22, 2017 /PRNewswire/ -- Vance Thompson Vision, an anterior segment, refractive surgery and research facility,inserted the first CyPass Micro-Stent in the region on March 20, 2017. The CyPass shunt is a minimally invasive device designed to reduce intraocular pressure in adults with mild to moderate glaucoma. The FDA has also approved
The CyPass Micro-Stent device is implanted during cataract surgery. It is designed to lower intraocular pressure by enhancing aqueous outflow through one of the natural drainage pathways of the eye, with minimal tissue disruption, which allows the excess fluid in the eye to drain.
Dr. Michael Greenwood, an ophthalmologist at Vance Thompson Vision in Fargo, N.D, was the first to perform a procedure using the CyPass device in the region. The procedure will complement the category of Minimally Invasive Glaucoma Surgery, or MIGS, and add to the surgeon's arsenal of tools to combat this disease.
"Our research demonstrates that this procedure can help provide excellent outcomes for patients," Dr. Greenwood says. "We are excited to bring this technology to the area."
More than 60 million people globally are affected by glaucoma that can lead to progressive damage of the optic nerve. Early diagnosis of glaucoma is critical to manage the disease, as it is often asymptomatic and therefore can go undetected until it is at an advanced stage. As the disease progresses, patients may experience loss of peripheral (side) vision, tunnel vision or eye spots. Glaucoma can eventually result in gradual, irreversible loss of vision and blindness. The exact cause of glaucoma is unknown.
"Glaucoma is the second leading cause of blindness in the world, behind only cataracts," says Dr. Michael Greenwood, a surgeon at Vance Thompson Vision in Fargo, ND. "We are excited to be part of new procedures that give patients more access to technologies that can help curb this disease."
For more information, visit www.vancethompsonvision.com.
About Vance Thompson VisionVance Thompson Vision, Sioux Falls, SD and Fargo, ND, is a world-class refractive surgery center and research institute. Vance Thompson Vision provides and participates in developing the world's most exceptional technologies to improve outcomes in surgical care; all while creating a patient experience that is second to none. With more than 100,000 procedures, more than 80 FDA monitored clinical trials, and having traveled the world to advance the learning of providers everywhere, Vance Thompson Vision is the standard in quality and innovation. For more information on the international reputation of the doctors that lead studies such as this one visit the biographies of Dr. Vance Thompson, Dr. Alison Tendler, Dr. John Berdahl, Dr. Michael Greenwood, Dr. Doug Wallin, Dr. Keith Rasmussen, Dr. Justin Schweitzer, Dr. Jason Schmit, and Dr. Mitch Ibach.
Matt Jensen, CEOVance Thompson Visionmatt.email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vance-thompson-vision-first-to-use-cypass-micro-stent-in-the-area-300427980.html
SOURCE Vance Thompson Vision
Subscribe to our Free Newsletters!